http://www.oncologynurseadvisor.com Latest articles from ONA Breast Cancer ONA Breast Cancer Breast cancer news and feature articles for oncology nurses. Breast Cancer Admin@haymarketmedia.com no Patients at higher or lower risk for having their cancer recur elsewhere in the body more than 5 years after diagnosis can be differentiated by a gene expression test. The test measures the expression levels of 58 genes in estrogen receptor-positive breast cancers. These research results were presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. http://www.oncologynurseadvisor.com/late-recurrence-risk-in-breast-cancer-differentiated-by-gene-expression-test/article/294641/ Fri, 24 May 2013 13:00:00 GMT Patients at higher or lower risk for having their cancer recur elsewhere in the body more than 5 years after diagnosis can be differentiated by a gene expression test. The test measures the expression levels of 58 genes in estrogen receptor-positive breast cancers. These research results were presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. ONA Breast cancer has variability from the different cell types with different patterns of gene expression in breast cancer, but a new study found that that variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients. These findings were presented at the 5th IMPAKT Breast Cancer Conference. http://www.oncologynurseadvisor.com/variability-in-breast-cancer-not-a-barrier-for-predictive-testing/article/294556/ Thu, 23 May 2013 19:00:00 GMT Breast cancer has variability from the different cell types with different patterns of gene expression in breast cancer, but a new study found that that variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients. These findings were presented at the 5th IMPAKT Breast Cancer Conference. ONA Among women with estrogen-receptor positive breast cancer, late recurrence was best predicted by the clinical treatment score. Significant prognostic value was added by the PAM50 risk of recurrence score and by the Breast Cancer Index score, according to a study comparing five scores that was presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. http://www.oncologynurseadvisor.com/late-recurrence-in-estrogen-positive-breast-cancer-predicted-by-genetic-and-clinical-factors/article/294552/ Thu, 23 May 2013 13:32:27 GMT Among women with estrogen-receptor positive breast cancer, late recurrence was best predicted by the clinical treatment score. Significant prognostic value was added by the PAM50 risk of recurrence score and by the Breast Cancer Index score, according to a study comparing five scores that was presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. ONA Women with breast cancer who had the strongest social relationships were likeliest to report fewer symptoms and the best overall quality of life. http://www.oncologynurseadvisor.com/social-ties-improve-physical-symptoms-after-breast-cancer-diagnosis/article/294299/ Thu, 23 May 2013 11:00:00 GMT Women with breast cancer who had the strongest social relationships were likeliest to report fewer symptoms and the best overall quality of life. ONA Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved. http://www.oncologynurseadvisor.com/everolimus-overcomes-trastuzumab-resistance-in-her2-early-breast-cancer/article/294281/ Wed, 22 May 2013 18:30:00 GMT Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved. ONA A new study shows a significant correlation between poorer performance on neuropsychological tests and memory complaints in posttreatment, early-stage breast cancer patients—particularly those who have undergone combined chemotherapy and radiation. http://www.oncologynurseadvisor.com/scientific-basis-for-cognitive-complaints-of-breast-cancer-patients-found/article/293686/ Fri, 17 May 2013 13:00:00 GMT A new study shows a significant correlation between poorer performance on neuropsychological tests and memory complaints in posttreatment, early-stage breast cancer patients—particularly those who have undergone combined chemotherapy and radiation. ONA Aerobic exercise may reduce breast cancer risk by changing estrogen metabolism to produce more of the metabolites that keep the disease at bay. http://www.oncologynurseadvisor.com/exercise-may-lower-breast-cancer-risk-by-altering-estrogen-metabolism/article/293342/ Wed, 15 May 2013 11:00:00 GMT Aerobic exercise may reduce breast cancer risk by changing estrogen metabolism to produce more of the metabolites that keep the disease at bay. ONA A new retrospective study suggests that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer who harbor specific mutations in the HER2 protein. http://www.oncologynurseadvisor.com/anti-her2-treatments-may-benefit-some-patients-with-lung-cancer/article/293329/ Tue, 14 May 2013 18:30:00 GMT A new retrospective study suggests that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer who harbor specific mutations in the HER2 protein. ONA Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug tamoxifen, according to a recent study. http://www.oncologynurseadvisor.com/coffee-may-decrease-risk-of-breast-cancer-returning/article/293238/ Tue, 14 May 2013 13:00:00 GMT Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug tamoxifen, according to a recent study. ONA Integrated 2-dimensional (2D) and 3-dimensional (3D) mammography improves the detection of breast cancer and reduces false-positive findings. http://www.oncologynurseadvisor.com/combining-2d-and-3d-digital-mammography-enhances-screening/article/293170/ Tue, 14 May 2013 11:00:00 GMT Integrated 2-dimensional (2D) and 3-dimensional (3D) mammography improves the detection of breast cancer and reduces false-positive findings. ONA http://www.oncologynurseadvisor.com/clinical-trial-addition-of-carboplatin-to-neoadjuvant-therapy-for-triple-negative-and-her2-positive-early-breast-cancer-geparsixto/article/243219/ Tue, 29 May 2012 16:44:22 GMT ONA A look at the following clinical trial: MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer http://www.oncologynurseadvisor.com/clinical-trial-mirna-profiling-of-breast-cancer-in-patients-undergoing-neoadjuvant-or-adjuvant-treatment-for-locally-advanced-inflammatory-breast-cancer/article/207418/ Thu, 14 Jul 2011 15:43:17 GMT A look at the following clinical trial: MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer ONA A look at the following clinical trial: Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer http://www.oncologynurseadvisor.com/clinical-trial-pre-surgery-positron-emission-mammography-in-patients-with-newly-diagnosed-breast-cancer/article/207417/ Thu, 14 Jul 2011 15:36:33 GMT A look at the following clinical trial: Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer ONA A look at the following clinical trial: Circadian Disturbances After Breast Cancer Surgery (CIRCA) http://www.oncologynurseadvisor.com/clinical-trial-circadian-disturbances-after-breast-cancer-surgery-circa/article/207414/ Thu, 14 Jul 2011 15:30:07 GMT A look at the following clinical trial: Circadian Disturbances After Breast Cancer Surgery (CIRCA) ONA A look at the following clinical trial: Genomic Testing for Primary Breast Cancer http://www.oncologynurseadvisor.com/clinical-trial-genomic-testing-for-primary-breast-cancer/article/207400/ Thu, 14 Jul 2011 15:25:38 GMT A look at the following clinical trial: Genomic Testing for Primary Breast Cancer ONA